Downloads: 1 | Views: 249 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Research Paper | Pharmacy | India | Volume 11 Issue 9, September 2022 | Popularity: 4.9 / 10

Rate This Article!      

Evaluation of Treatment Outcome for HIV Patients after TLD Regimen (Tenofovir, Lamivudine and Dolutegravir) using Viral Load Suppression

D. Vasuni Sai Mounika, K. Lokesh, Md. Salma Sulthana, A. Sudharshan Reddy

Abstract: Introduction: HIV is a virus that weakens the immune system of a person by destroying cells that fight against infection and disease. Dolutegravir-based regimens (TLD/ALD) were suggested by the WHO as the preferred first- and second-line antiretroviral therapy in 2018. Objective: To evaluate the treatment outcome of TLD regimen based on viral load suppression among HIV patients. Methods: A prospective observational study was conducted in government general hospital, Ongole for a period of six months. Efficacy of TLD regimen among 470 patients was assessed. Results: Our study involves 3,110 patients out of which 470 patients are included who are having age between 20-50 years old, undergoing TLD therapy, who are under follow up and whose medication adherence is documented. Of these patients, 321 individuals (68%) had virologic response to the TLD regimen, while virologic response was not achieved in 149 patients (32%). Conclusion: According to the results of our study, we conclude that the TLD regimen is 68% effective, andPatients in clinical stage 1, who had >95% adherence, were working, between the ages of 20 and 30, females showed better results in terms of viral suppression.

Keywords: HIV, Human immunodeficiency virus, TLD regimen, Tenofovir, Lamivudine and Dolutegravir, viral load, AIDS, Acquired immunodeficiency syndrome, Virologic suppression improvement

Edition: Volume 11 Issue 9, September 2022

Pages: 232 - 234

DOI: https://www.doi.org/10.21275/MR22829111443

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article